The catch: lawful and regulatory certainty is minimal. Retatrutide was under no circumstances over the FDA drug lack record (because it was in no way accredited), so compounders giving it run underneath additional tenuous authorized framing than those who taken care of semaglutide or tirzepatide during the 2023–2024 shortages. Pricing might shift